Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

The Moreau Strain of Bacillus Calmette-Guerin (BCG) for High-Risk Non-Muscle Invasive Bladder Cancer: An Alternative during Worldwide BCG Shortage?

Hofbauer SL, Shariat SF, Chade DC, Sarkis AS, Ribeiro-Filho LA, Nahas WC, Klatte T.

Urol Int. 2016;96(1):46-50. doi: 10.1159/000440701. Epub 2015 Nov 11.

PMID:
26555711
2.

Plasmacytoid urothelial carcinoma: a case of histological variant of urinary bladder cancer with aggressive behavior.

da Fonseca LG, Souza CE, Mattedi RL, Girardi DM, Sarkis ÁS, Hoff PMG.

Autops Case Rep. 2014 Mar 30;4(4):57-61. doi: 10.4322/acr.2014.040. eCollection 2014 Oct-Dec.

3.

Organ-sparing microsurgical resection of incidental testicular tumors plus microdissection for sperm extraction and cryopreservation in azoospermic patients: surgical aspects and technical refinements.

Hallak J, Cocuzza M, Sarkis AS, Athayde KS, Cerri GG, Srougi M.

Urology. 2009 Apr;73(4):887-91; discussion 891-2. doi: 10.1016/j.urology.2008.08.510. Epub 2009 Feb 8.

PMID:
19201456
4.

Benign glandular inclusion in obturator lymph node of a man treated for prostate carcinoma.

Moreira Leite KR, Sarkis AS, Camara-Lopes LH.

Pathol Int. 2007 Jul;57(7):454-7.

PMID:
17587246
5.

Microvascular tumour invasion in renal cell carcinoma: the most important prognostic factor.

Dall'Oglio MF, Antunes AA, Sarkis AS, Crippa A, Leite KR, Lucon AM, Srougi M.

BJU Int. 2007 Sep;100(3):552-5. Epub 2007 Jun 6.

6.

[Brazilian Society of Urology. Guidelines on penile neoplasm].

Gonzaga-Silva LF, Zequi Sde C, Nardi AC, Carvalhal GF, de Almeida JC, Pompeo AC, Scaletscky R, Cavalcanti AG, Ornellas AA, Fonseca CE, Ferreira U, Machado MT, da Silva EA, dos Santos Júnior MW, Sarkis AS, Bretas FF, Araújo RM, Brandão Filho MR, Dubourq F.

Int Braz J Urol. 2007 Mar-Apr;33 Suppl 1:55-75. Portuguese. No abstract available.

PMID:
23638468
7.

Identification of differentially expressed genes in prostatic epithelium in relation to androgen receptor CAG repeat length.

Coutinho-Camillo CM, Miracca EC, dos Santos ML, Salaorni S, Sarkis AS, Nagai MA.

Int J Biol Markers. 2006 Apr-Jun;21(2):96-105.

PMID:
16847812
8.

Differentially expressed genes in the prostate cancer cell line LNCaP after exposure to androgen and anti-androgen.

Coutinho-Camillo CM, Salaorni S, Sarkis AS, Nagai MA.

Cancer Genet Cytogenet. 2006 Apr 15;166(2):130-8.

PMID:
16631469
9.

Double-barreled wet colostomy is a safe option for simultaneous urinary and fecal diversion. Analysis of 56 procedures from a single institution.

Guimaraes GC, Ferreira FO, Rossi BM, Aguiar S Jr, Zequi SC, Bachega W, Nakagawa WT, Fonseca FP, Sarkis AS, Lopes A.

J Surg Oncol. 2006 Mar 1;93(3):206-11.

PMID:
16482600
10.

The transcripts of SFRP1,CEP63 and EIF4G2 genes are frequently downregulated in transitional cell carcinomas of the bladder.

Buim ME, Soares FA, Sarkis AS, Nagai MA.

Oncology. 2005;69(6):445-54. Epub 2006 Jan 12.

PMID:
16410684
11.

Treatment of patients with superficial bladder cancer stratified by risk groups treated with lyophilized Moreau-Rio de Janeiro BCG strain.

Fonseca FP, Bachega W Jr, Zequi SC, Sarkis AS, Guimaraes G, Priante AV, Lopes A.

Int Braz J Urol. 2002 Sep-Oct;28(5):426-35; discussion 435-6.

12.

Vitamin D receptor polymorphisms and prostate cancer risk in Brazilian men.

Maistro S, Snitcovsky I, Sarkis AS, da Silva IA, Brentani MM.

Int J Biol Markers. 2004 Jul-Sep;19(3):245-9.

PMID:
15503828
13.

Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands.

Arap MA, Lahdenranta J, Mintz PJ, Hajitou A, Sarkis AS, Arap W, Pasqualini R.

Cancer Cell. 2004 Sep;6(3):275-84.

14.

Androgen receptor CAG repeat polymorphism in prostate cancer from a Brazilian population.

Santos ML, Sarkis AS, Nishimoto IN, Nagai MA.

Cancer Detect Prev. 2003;27(5):321-6.

PMID:
14585317
15.
16.

Human papillomavirus DNA and p53 status in penile carcinomas.

Levi JE, Rahal P, Sarkis AS, Villa L.

Int J Cancer. 1998 Jun 10;76(6):779-83.

17.

Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC.

Sarkis AS, Bajorin DF, Reuter VE, Herr HW, Netto G, Zhang ZF, Schultz PK, Cordon-Cardo C, Scher HI.

J Clin Oncol. 1995 Jun;13(6):1384-90.

PMID:
7751883
18.

Family history of cancer, body weight, and p53 nuclear overexpression in Duke's C colorectal cancer.

Zhang ZF, Zeng ZS, Sarkis AS, Klimstra DS, Charytonowicz E, Pollack D, Vena J, Guillem J, Marshall JR, Cordon-Cardo C, et al.

Br J Cancer. 1995 Apr;71(4):888-93.

19.

p53 nuclear overexpression: an independent predictor of survival in lymph node--positive colorectal cancer patients.

Zeng ZS, Sarkis AS, Zhang ZF, Klimstra DS, Charytonowicz E, Guillem JG, Cordon-Cardo C, Cohen AM.

J Clin Oncol. 1994 Oct;12(10):2043-50.

PMID:
7931472
20.

Altered patterns of MDM2 and TP53 expression in human bladder cancer.

Lianes P, Orlow I, Zhang ZF, Oliva MR, Sarkis AS, Reuter VE, Cordon-Cardo C.

J Natl Cancer Inst. 1994 Sep 7;86(17):1325-30.

PMID:
8064890
21.

Association of P53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder.

Sarkis AS, Dalbagni G, Cordon-Cardo C, Melamed J, Zhang ZF, Sheinfeld J, Fair WR, Herr HW, Reuter VE.

J Urol. 1994 Aug;152(2 Pt 1):388-92.

PMID:
8015077
22.

Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma.

Aprikian AG, Sarkis AS, Fair WR, Zhang ZF, Fuks Z, Cordon-Cardo C.

J Urol. 1994 May;151(5):1276-80.

PMID:
8158773
23.

Bladder cancer: advances in biology and treatment.

Bosl GJ, Fair WR, Herr HW, Bajorin DF, Dalbagni G, Sarkis AS, Reuter VE, Cordon-Cardo C, Sheinfeld J, Scher HI.

Crit Rev Oncol Hematol. 1994 Feb;16(1):33-70. Review.

PMID:
8074800
24.

Tobacco smoking, occupation, and p53 nuclear overexpression in early stage bladder cancer.

Zhang ZF, Sarkis AS, Cordon-Cardo C, Dalbagni G, Melamed J, Aprikian A, Pollack D, Sheinfeld J, Herr HW, Fair WR, et al.

Cancer Epidemiol Biomarkers Prev. 1994 Jan-Feb;3(1):19-24.

25.

Genetic alterations associated with bladder cancer.

Cordon-Cardo C, Dalbagni G, Sarkis AS, Reuter VE.

Important Adv Oncol. 1994:71-83. Review. No abstract available.

PMID:
7911446
26.

Biological markers of prognosis in transitional cell carcinoma of the bladder: current concepts.

Aprikian AG, Sarkis AS, Reuter VE, Cordon-Cardo C, Sheinfeld J.

Semin Urol. 1993 Aug;11(3):137-44. Review. No abstract available.

PMID:
8210835
27.

Molecular genetic alterations of chromosome 17 and p53 nuclear overexpression in human bladder cancer.

Dalbagni G, Presti JC Jr, Reuter VE, Zhang ZF, Sarkis AS, Fair WR, Cordon-Cardo C.

Diagn Mol Pathol. 1993 Mar;2(1):4-13.

PMID:
7904525
28.

Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.

Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhang ZF, Sheinfeld J, Fair WR, Herr HW, Reuter VE.

J Natl Cancer Inst. 1993 Jan 6;85(1):53-9.

PMID:
7677935
29.

Blood group antigens in normal and neoplastic urothelium.

Sheinfeld J, Reuter VE, Sarkis AS, Cordon-Cardo C.

J Cell Biochem Suppl. 1992;16I:50-5. Review.

PMID:
1305688

Supplemental Content

Loading ...
Support Center